Lusvertikimab
Modify Date: 2024-01-14 13:11:30
Lusvertikimab structure
|
Common Name | Lusvertikimab | ||
|---|---|---|---|---|
| CAS Number | 2375835-91-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LusvertikimabLusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research[1]. |
| Name | Lusvertikimab |
|---|
| Description | Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research[1]. |
|---|---|
| Related Catalog | |
| Target |
IL7R |
| In Vitro | OSE-127 (4 天) 可阻断 IL7 依赖性 ALL 细胞系和患者来源的异种移植 (PDX) 样本中的 STAT5 磷酸化[2]。 |
| In Vivo | 当相应的对照小鼠显示出明显白血病的临床症状时，OSE-127 处理的小鼠体内 21/22 (95%) PDX 样本显示外周血 (PB) 母细胞减少[1]。 |
| References |
| No Any Chemical & Physical Properties |